Announcement – New Cancer Center Opening at 8613 Lee Highway, Fairfax, Virginia, 22031: The Fairfax office previously located at 8503 Arlington Blvd, Suite 400, has RELOCATED as of April 13th 2021. (Entrance is around on the side – the side not facing Lee Highway) – see here

COVID19 Update: All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Alex Spira, MD PhD FACP VCS Co-Author Virginia Cancer Specialists - JAMA Network - Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas Clinical Trial

Virginia Cancer Specialists Practice Blog

April 09, 2020
Virginia Cancer Specialists » VCS Practice News » Physicians » VCS Practice News » Alex Spira MD PhD FACP » Alex Spira, MD PhD FACP VCS Co-Author Virginia Cancer Specialists – JAMA Network – Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas Clinical Trial
Alex Spira, MD PhD FACP VCS Co-Author Virginia Cancer Specialists – JAMA Network – Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas Clinical Trial

Question  In patients with advanced soft tissue sarcoma (STS), does the addition of olaratumab to doxorubicin improve overall survival?

Findings  In this randomized clinical trial of 509 adults with advanced STS, there was no significant difference in overall survival between patients who received doxorubicin plus olaratumab and patients who received doxorubicin plus placebo in the total STS and leiomyosarcoma populations (total STS: hazard ratio, 1.05; median, 20.4 vs 19.7 months; leiomyosarcoma: hazard ratio, 0.95; median, 21.6 vs 21.9 months).

Meaning  There was no significant difference in overall survival with the addition of olaratumab to doxorubicin in patients with advanced STS.

Link to Study Findings Here

#Sarcoma #cancerresearch